DCAP Antimicrobial Compounds Targeting Bacterial Membranes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial compounds are ineffective against slow-growing bacteria and those in biofilms, leading to drug resistance and relapse of infections, as they primarily target rapidly growing cells and are not specific to bacterial membranes, particularly failing against Gram-negative bacteria.
Innovation Solution
Development of a family of compounds, including (2-((3-(3,6-dichloro-9H-carbazol-9-yl)-2-hydroxypropyl)amino)-2-(hydroxymethyl)propane-1,3-diol (DCAP) and its derivatives, which target both Gram-positive and Gram-negative bacterial membranes by altering the cell envelope properties, disrupting membrane potential and permeability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional antibiotics (e.g., β-lactams) are used to treat bacterial infections, then rapidly growing cells are effectively targeted and killed, but slow-growing and dormant bacteria survive and cause relapse
Solution Approach 1:
The patent changes the target parameter from growth-dependent processes (peptidoglycan synthesis) to growth-independent processes (membrane integrity). The compound DCAP and its derivatives act on the bacterial membrane regardless of growth rate, thereby killing both rapidly growing and slow-growing/dormant bacteria effectively.
2Reliability
If membrane-targeting compounds are used to combat slow-growing bacteria, then dormant and biofilm-associated bacteria are effectively killed, but there is a risk of affecting eukaryotic membranes and lack of Gram-negative coverage
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (amphipathic structure with hydrophobic and hydrophilic regions) that enable selective interaction with bacterial membranes. The compounds exploit differences in membrane composition between bacteria and eukaryotes, and between Gram-negative and Gram-positive bacteria, achieving both specificity and broad-spectrum activity.
Solution Approach 2:
The patent modifies key parameters of membrane-active compounds including molecular weight, hydrophobicity, and charge distribution to optimize penetration through the outer membrane of Gram-negative bacteria while maintaining selectivity for bacterial over eukaryotic membranes. This enables broad-spectrum activity across all bacterial types.
3Productivity
If antibiotics requiring fast metabolism and growth are used, then treatment of actively dividing bacteria is effective, but dormant bacteria survive and develop drug resistance
Solution Approach 1:
Instead of targeting metabolic processes that are active only in growing cells, the patent inverts the approach by targeting the membrane structure itself, which must be maintained in all bacterial cells regardless of growth state. This growth-independent mechanism eliminates the selective pressure that drives resistance development in dormant populations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DCAP effectively inhibits bacterial growth and kills bacteria by depolarizing the membrane potential and increasing membrane permeability, while being inert to mammalian membranes, thus addressing the limitations of existing antimicrobial agents.
Implementation Method 1
DCAP effectively inhibits bacterial growth and kills bacteria by depolarizing the membrane potential
Implementation Method 2
increasing membrane permeability
Data Source
AI summary
Described herein are antimicrobial compounds identified via a high-throughput inhibitor screen of the in vitro activity of MipZ, which is an ATPase that regulates division site placement in Caulobacter crescentus. The compounds and their analogs are active against bacterial membranes and thus represent a novel class of antimicrobial compounds. The antimicrobial compounds are effective against both actively growing bacterial cells as well as bacterial cells in the stationary phase. The antimicrobial compounds are also effective against bacteria in biofilms.